Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HCT for Lysosomal and Peroxisomal Inborn Errors of Metabolism
NCT00668564Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2008
- Primary completion
- Feb 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in lysosomal storage disease (LSD), peroxisomal disorder, sponsored by Masonic Cancer Center. Started Mar 2008; status: terminated.
02
Drugs
alemtuzumab
03
Conditions
lysosomal storage disease (LSD)peroxisomal disorder
Beyond the preview
Go deeper on NCT00668564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00668564.